The National Institute for Health and Care Excellence

New treatment option recommended for recurrent or metastatic cervical cancer

A new treatment option is now available on the NHS for cervical cancer that has come back or spread to other parts of the body, following our final draft guidance published today.
The National Institute for Health and Care Excellence

First disease-modifying therapy to delay the onset of type 1 diabetes recommended for NHS use

Teplizumab is the disease-modifying therapy for type 1 diabetes and England is the first country in Europe to recommend it's use through a health technology appraisal.
The National Institute for Health and Care Excellence

From £1 to £180: how NICE guidance helped us make smarter slide sheet choices

NICE’s healthtech guidance provided me with the perfect catalyst for change.
National Institute for Health and Care Excellence

In consultation: Guidance and quality standards

Secukinumab for treating relapsed polymyalgia rheumatica ID6599 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators Technology appraisal ...
National Institute for Health and Care Excellence

Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer

There is a simple discount patient access scheme for mirvetuximab soravtansine. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Ectopic pregnancy and miscarriage: diagnosis and initial management NG126 17 April 2019 17 June 2026 Ectopic pregnancy and miscarriage QS69 10 September 2014 17 June 2026 ...
National Institute for Health and Care Excellence

Attention deficit hyperactivity disorder: diagnosis and management

This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well ...
National Institute for Health and Care Excellence

Drug misuse

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
National Institute for Health and Care Excellence

Rheumatoid arthritis in adults: management

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259] ...
National Institute for Health and Care Excellence

Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

There is a simple discount patient access scheme for mepolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact UK.pas@gsk.com ...
National Institute for Health and Care Excellence

Acne vulgaris: management

Decisions about updating our guidance are made by NICE’s prioritisation board. For more information on the principles and process, see NICE-wide topic prioritisation: the manual. For information about ...